A Parallel, Open-Label, Single-Dose Administration, Phase 1 Clinical Study to Assess the Safety and Pharmacokinetics of AD-104-A in Healthy Adult Volunteers and Patients With Renal Impairment
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-104-A
An open label, randomized, single dose, 2-sequence, 2-period, cross-over phase 1 study to evaluate the safety and pharmacokinetics comparison of AD-104 in healthy adult volunteers